Kinfo
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCTNASDAQHealthcare·US · USD
$6.71
-0.26 (-3.73%)
Prices as of July 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap190.72M USD
Enterprise value10.72M USD
Trailing P/E10.08
Forward P/E-1.73
PEG ratio0.12
Price / sales3.62
Price / book1.04
Profitability
Gross margin0.00%
Operating margin-1403.74%
Profit margin-143.80%
Return on assets-19.14%
Return on equity-37.01%
Income (TTM)
Revenue54.71M USD
Gross profit-44.14M USD
EBITDA-85.48M USD
Net income-78.67M USD
Diluted EPS-$2.83
Rev. growth (YoY)-93.00%
Balance sheet
Total cash211.38M USD
Total debt23.99M USD
Debt / equity12.54
Current ratio6.31
Book value / share$6.73
Cash flow (TTM)
Operating cash flow-58.57M USD
Levered free cash flow11.29M USD
Shares & price
Shares outstanding28.42M
Float26.15M
Held by institutions80.30%
Beta2.36
50-day MA$7.55
200-day MA$8.98
52-week high$24.17
52-week low$5.85
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-11-0.33-0.09+72.73%2026-05-07-1.01-0.95+5.94%2026-03-03-0.76-1.03−35.53%2025-11-10-0.80-0.49+38.75%2025-09-231.232.36+91.87%
About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joseph E. Payne M.Sc.
Employees
106
Headquarters
San Diego, CA, United States

Frequently asked questions about Arcturus Therapeutics Holdings Inc.